t e c h n i c a l r e p o r t s
There is growing evidence of shared risk alleles for complex traits (pleiotropy), including autoimmune and neuropsychiatric diseases. This might be due to sharing among all individuals (whole-group pleiotropy) or a subset of individuals in a genetically heterogeneous cohort (subgroup heterogeneity). Here we describe the use of a well-powered statistic, BUHMBOX, to distinguish between those two situations using genotype data. We observed a shared genetic basis for 11 autoimmune diseases and type 1 diabetes (T1D; P < 1 × 10 -4 ) and for 11 autoimmune diseases and rheumatoid arthritis (RA; P < 1 × 10 -3 ). This sharing was not explained by subgroup heterogeneity (corrected P BUHMBOX > 0.2; 6,670 T1D cases and 7,279 RA cases). Genetic sharing between seronegative and seropostive RA (P < 1 × 10 -9 ) had significant evidence of subgroup heterogeneity, suggesting a subgroup of seropositive-like cases within seronegative cases (P BUHMBOX = 0.008; 2,406 seronegative RA cases). We also observed a shared genetic basis for major depressive disorder (MDD) and schizophrenia (P < 1 × 10 -4 ) that was not explained by subgroup heterogeneity (P BUHMBOX = 0.28;
9,238 MDD cases).
Recent studies have demonstrated that many diseases have risk alleles in common [1] [2] [3] [4] and exhibit significant coheritability [5] [6] [7] . Coheritability studies are defining the relationship between complex traits and providing new insights into disease mechanisms. As more phenotypes are studied using genetics in the context of emerging deeply phenotyped population-wide cohorts 8 , including the Precision Medicine Initiative 9 , coheritability of traits will become even more apparent. In the genomics era, methods for detecting coheritability have moved beyond traditional approaches such as twin or family studies 10, 11 . Now, alternative approaches using genome-wide association study (GWAS) data from unrelated individuals are widely used. Polygenic risk score approaches 3, 12, 13 build genetic risk scores (GRSs) for one phenotype and test the association of those GRSs with a second phenotype. Mixed-model approaches 5, 6, 14 can be used to estimate the genetic covariance of two traits on the observed scale. Genetic covariance can be used to calculate genetic correlation and coheritability 6 . Cross-trait linkage disequilibrium score regression (LDSC) uses linkage disequilibrium (LD) and summary statistics obtained from GWAS to estimate the genetic correlation attributable to SNPs 7 . In addition, the P values of independent SNPs associated with multiple phenotypes can be tested for a significant deviation from the null distribution 2 .
A method to decipher pleiotropy by detecting underlying heterogeneity driven by hidden subgroups applied to autoimmune and neuropsychiatric diseases t e c h n i c a l r e p o r t s These approaches have been applied to demonstrate significant shared genetic structure among many phenotypes 5, 7, 15 , including autoimmune 2 and neuropsychiatric diseases 3, 6, 13 . The observed coheritability and genetic sharing suggest the possibility of pleiotropy, defined here as the sharing of risk alleles across traits at specific loci or at a genome-wide level. An example of a variant showing pleiotropy is the PTPN22 variant encoding p.Arg620Trp, which is associated with multiple autoimmune diseases 16 .
The sharing of risk alleles across diseases can be driven by all individuals or by a subset of individuals. In the former scenario, the sharing is clearly driven by pleiotropy (whole-group pleiotropy). In the latter scenario, only a subset of individuals with one disease is genetically similar to individuals with another disease. We call this subgroup heterogeneity, a situation where a patient cohort consists of genetically distinct subgroups that may or may not have distinct symptom profiles and treatment outcomes. Subgroup heterogeneity can occur in the context of misclassifications (for example, when cases with atypical clinical presentations for a different disease are erroneously included), molecular subtypes (for example, when two different etiologies underlie a disease, resulting in a subset of cases that share pathogenesis with a different disease), asymmetric causal relationships (for example, when one disease causes another disease, resulting in a subset of cases that also have the causal disease; often called mediated pleiotropy), or ascertainment bias (for example, when cases also affected with a different disease are more likely to come to clinical attention and be included in the study). Such situations result in a subset of cases that is genetically similar to individuals with another disease, creating shared genetic structure 17 . Indeed, there is now evidence that misclassifications [18] [19] [20] [21] , etiological diversity 22 , and ascertainment bias 23 are prevalent across certain human diseases, leading to the conclusion that significant heterogeneity may exist [24] [25] [26] [27] . Because the potential contribution of subgroup heterogeneity to any genetic sharing observed between diseases represents a critical disease insight, statistical methods are needed to distinguish subgroup heterogeneity from whole-group pleiotropy. For the purposes of this paper, we will use the term 'pleiotropy' to refer to whole-group pleiotropy and 'heterogeneity' to refer to subgroup heterogeneity. To characterize the false positive rate (FPR) of BUHMBOX, we simulated 1,000,000 studies (N = 2,000 and M = 50) in which there was no heterogeneity (π = 0; Online Methods) or pleiotropy. BUHMBOX obtained a 5.1% FPR at P < 0.05; it also obtained appropriate FPRs at a wide range of statistical significance thresholds (P < 0.05 to P < 0.0005; Supplementary Table 2) .
RESULTS

Overview of BUHMBOX
To evaluate the FPR of BUHMBOX when there was pleiotropy without heterogeneity (π = 0), we simulated 1,000 studies (N = 2,000 and M = 50) assuming that D A and D B shared 10% of risk loci (5 loci). We quantified the proportion of instances in which BUHMBOX and GRS approaches obtained P values smaller than the threshold P < 0.05. The GRS approach appropriately demonstrated 64.8% power to detect shared genetic structure. BUHMBOX demonstrated an appropriate FPR of 4.3% in detecting heterogeneity (Supplementary Fig. 1) .
Finally, to evaluate the power of BUHMBOX to detect heterogeneity, we repeated these simulations assuming no pleiotropy but subtle heterogeneity. We assumed that 10% of D A cases were actually D B cases (π = 0.1). In this case, BUHMBOX demonstrated 81.7% power to detect heterogeneity at P < 0.05 (Supplementary Fig. 1) , and the GRS approach demonstrated 100% power to detect shared genetic structure. Note that the difference in power for the GRS approach in the pleiotropy and heterogeneity simulations is due to the stochastic chance that sampled effect sizes for all five loci may be small in the pleiotropy simulation; in simulations where we fixed the OR (1.25) and RAF (0.3) for all loci, the power of the GRS approach was similar for the two scenarios: 91.8% in pleiotropy and 92.0% in heterogeneity.
These simulations illustrate that BUHMBOX is sensitive to heterogeneity but robust to pleiotropy, whereas the GRS approach detects both scenarios and cannot be used to discriminate between the two. Thus, BUHMBOX complements methods for detecting pleiotropy by helping to interpret shared genetic structure (Supplementary Table 1 ).
Weighting pairwise correlations increases power BUHMBOX combines multiple pairwise correlations into one statistic. A pair of loci with larger allele frequencies and effect sizes will show larger expected correlation given the same π and may be more informative than other pairs of loci ( Supplementary Fig. 2 ). We hypothesized that accounting for this unequal information between SNP pairs could increase power. We defined a scheme to weight pairwise correlations between loci as a function of their effect sizes and allele frequencies (Online Methods). In simulations, we observed substantial power gain with this weighting scheme. Assuming 1,000 cases and 50 risk loci, we compared power for BUHMBOX implemented with and without weighting correlations (equation (12) in the Supplementary Note). Across a wide range of π values, we observed that weighting dramatically increased power (Fig. 2) . For example, at π = 0.1, the weighted implementation of BUHMBOX yielded 74% power, in comparison to the unweighted implementation, which yielded only 36% power.
Power is proportional to number of samples and loci
The statistical power of BUHMBOX is a function of many factors, including sample size N of the cases we are testing for heterogeneity, π, M, RAF, and OR. We sampled pairs of RAF and OR values from the GWAS catalog. Given a sample size of N = 2,000 cases and 2,000 controls, assuming π = 0.2 and 50 risk loci, BUHMBOX achieved 92% power at P < 0.05 (Fig. 3) . As many GWAS now consist of more than 2,000 cases and many diseases are approaching 50 known associated loci 28 , BUHMBOX is currently well powered to detect a moderate amount of heterogeneity (π = 0.2) for many human traits. Modest heterogeneity is more challenging to detect at this sample size; power decreased to 67% at π = 0.1 and to 38% at π = 0.05. Power can be augmented with larger sample size ( Fig. 3) and larger effect sizes ( Supplementary Fig. 3 ). Power can also be increased by including Figure 2 Power gain by weighting SNPs by allele frequency and effect size. Comparison of the statistical power of BUHMBOX with a weighting scheme that optimally weights correlations between SNPs (weighted) to that in an alternative approach that weights correlations uniformly (unweighted; equation (12) in the supplementary note). We simulated 1,000 case individuals and assumed 50 risk loci, whose ORs and RAFs were sampled from the GWAS catalog. Colored bands denote the 95% confidence intervals of the power estimates. proportion, when the number of risk loci was fixed at 50 (a), and of the number of risk loci and heterogeneity proportion, when the case sample size was fixed at 2,000 (b). We assumed that we had the same number of controls as cases. White lines denote 20%, 40%, 60%, and 80% power.
npg t e c h n i c a l r e p o r t s large numbers of loci with even nominal evidence of association in addition to established genome-wide significant loci ( Supplementary  Fig. 4 and Supplementary Note).
Controlling for linkage disequilibrium
Although BUHMBOX adequately controlled the FPR when loci were truly independent, we were concerned that long-range LD between apparently independent loci may introduce false positives 29 . To ensure that BUHMBOX was robust to LD, we implemented the following strategies: (i) stringent LD pruning of D B -associated loci to exclude SNPs with r 2 >0.1 and (ii) accounting for any remaining residual LD by assessing the relative increase of correlations in cases as compared to controls (delta correlations). We evaluated these strategies by measuring FPR using the RA Immunochip Consortium data 30 . In 1,000 different loosely pruned (r 2 <0.5) SNP sets constructed using the Sweden EIRA data (Online Methods), the FPR without using delta correlations was high (22.4% at P < 0.05). Applying delta correlations reduced this FPR to 9.5%. When we used stringent pruning (r 2 <0.1), FPR was appropriately controlled (FPR was 5.9% and 5.3% with and without delta correlations, respectively). Although LD pruning alone was sufficiently effective for FPR control in this simulation, we have used both strategies throughout the paper to be conservative.
Accounting for population stratification
Another potential confounding factor is population stratification. If population stratification exists, weak correlations between unlinked loci may occur, leading to inappropriate significance. If similar population stratification exists in cases and controls, the use of delta correlations mitigates this effect. To more aggressively control for the effect of stratification at the individual level, we implemented BUHMBOX 30 (Online Methods) to create a highly stratified data set. In 1,000 sets of randomly sampled independent SNPs, we observed an inflation of the FPR (8.6% at P < 0.05); this was appropriately corrected (FPR of 5.9% at P < 0.05) when we regressed out the effects of ten principal components.
Application to autoimmune diseases
Autoimmune diseases have genetic risk loci in common 2,4,32-36 that cluster in specific immune pathways 2, 27, 36 . We used the GRS approach to evaluate shared genetic structure for autoimmune diseases and then applied BUHMBOX to assess heterogeneity. We obtained individual-level genotype data from the Type 1 Diabetes Genetics Consortium (T1DGC) UK case-control cohort (6,670 cases and 9,416 controls) 37 and the RA Immunochip Consortium's six RA case-control cohorts (7,279 seropositive RA cases and 15,870 controls) 30 (Online Methods). We evaluated genetic sharing for a spectrum of autoimmune diseases with T1D and RA. We obtained independent associated loci for all 18 autoimmune diseases (r 2 <0.1, including MHC SNPs) from ImmunoBase (see URLs and Supplementary Table 3 ) and tested the association of GRSs for these autoimmune diseases with T1D and RA case status.
We observed substantial genetic sharing between autoimmune diseases. T1D demonstrated significant sharing with alopecia areata (AA), autoimmune thyroid disease (ATD), celiac disease (CEL), Crohn's disease (CRO), juvenile idiopathic arthritis (JIA), primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), RA, Sjögren's syndrome (SJO), systemic lupus erythematosus (SLE), and vitiligo (VIT) (positive association, P < 1 × 10 −4 ). RA exhibited significant genetic sharing with AA, ankylosing spondylitis (AS), ATD, CEL, JIA, PBC, PSC, SLE, systemic sclerosis (SSC), T1D, and VIT (P < 1 × 10 −3 ). Overall, GRSs showed significant positive associations for 11 autoimmune diseases each in the T1D and RA cohorts (GRS P < 2.9 × 10 −3 = 0.05/17, correcting for 17 diseases tested; Table 1 and  Supplementary Table 4) . We considered only these traits for subsequent analyses. To evaluate the degree of heterogeneity necessary to achieve the observed genetic sharing for these autoimmune diseases, we calculated the GRS regression coefficient, which we previously showed approximates the expected π (ref. 38) , assuming no pleiotropy. 
On the basis of the GRS coefficients, we observed π estimates ranging from 0.08 to 0.76 across the different autoimmune diseases in T1D and from 0.10 to 0.43 in RA (Fig. 4 and Table 1 ).
We estimated the power of BUHMBOX to detect heterogeneity, correcting for 11 tests (P < 4.5 × 10 −3 ). BUHMBOX was well powered for some autoimmune traits; at π = 0.2, four traits had >90% power for T1D and four traits had >90% power for RA (Fig. 5) . Despite this, we observed no evidence of heterogeneity at all (corrected P > 0.2; Fig. 6 and Table 1 ). Our findings suggest that autoimmune diseases have risk alleles and pathways in common with T1D and RA, and this is not caused by subgroups of genetically similar cases resulting from misclassifications or molecular subtypes.
Application to subtype misclassifications in RA RA consists of two subtypes, seropositive and seronegative RA, with distinct clinical outcomes and MHC associations 38 . Patients are classified into these two subtypes by whether they have serological evidence of antibodies reactive to cyclic citrullinated peptides (CCP). Although testing for antibody to CCP is specific, its lack of sensitivity can result in some patients with seropositive RA being misclassified as seronegative for RA 20 . We have previously demonstrated that there is shared genetic structure for seropositive and seronegative RA using the GRS approach 38 , which could imply misclassifications of up to 26.3% of cases between the two RA subtypes.
We used BUHMBOX to evaluate whether seropositive RA misclassifications were present in a seronegative RA cohort. We used the seronegative RA cohort (2,406 cases and 15,870 controls) from the RA Immunochip Consortium 30 . Among 68 independent RA-associated loci, we chose SNPs that were associated with seropositive RA (P < 5 × 10 −8 ) but not with seronegative RA (P > 5 × 10 −8 ) in our Immunochip data. This criterion resulted in the selection of 14 specific loci exclusively associated with seropositive RA (Supplementary Table 3 ). The seropositive RA GRS was significantly associated with seronegative RA case status (β = 0.30, P = 1.1 × 10 −10 ). The regression coefficient (β = 0.30) represents an upper bound for π (Fig. 4) . BUHMBOX suggested that heterogeneity was indeed present (P = 0.008; Fig. 6 , Table 1, and Supplementary Table 4) , consistent with potential subtype misclassifications. As a more stringent test, we selected SNPs on the basis of the results from a test for heterogeneity between the RA subtypes; for this test, we obtained P values by assigning individuals with seropositive RA as cases and individuals with seronegative RA as controls. We chose both SNPs that were associated with seropositive RA (P < 5 × 10 −8 ) and were nominally significant in the heterogeneity test between the RA subtypes (P < 0.05; Supplementary Table 3) . Applying BUHMBOX to these 12 loci still showed significant heterogeneity in the seronegative RA cohort (P = 0.017).
Application to major depressive disorder and schizophrenia
Current definitions of psychiatric disorders reflect clinical syndromes, with overlapping clinical features. As a result, psychiatric diagnoses for a patient may change as their symptoms evolve 21 . In addition to the potential for misdiagnosis, a subset of true MDD cases may be genetically more similar to schizophrenia. If heterogeneity with respect to schizophrenia risk alleles exists among MDD cases, then genetic studies would suggest evidence of coheritability for the two disorders 17 , as has been observed in previous studies 3, 6, 7 . The unintentional inclusion npg t e c h n i c a l r e p o r t s of 'schizophrenia-like' MDD cases, owing to diagnostic misclassification or genetically distinct subgroups, has been acknowledged and explored as a potential source of bias in coheritability studies by previous investigators 3, 17 .
We used BUHMBOX to test for a subgroup of schizophrenia-like cases in MDD. If a subset of MDD cases were misdiagnosed and in fact had schizophrenia or were more genetically similar to schizophrenia, we would expect to see subgroup heterogeneity among MDD cases with respect to schizophrenia risk loci. We first evaluated evidence of shared genetic structure among 90 known schizophrenia-associated loci 39 Table 6 ) 3, 6, 7 , the schizophrenia GRS was associated with MDD case status (P = 1.54 × 10 −5 ), indicating shared genetic structure (Fig. 4) . For the GRS analysis, we used a refined subset of the total sample (6,382 MDD cases and 5,614 controls), excluding samples that overlapped with the schizophrenia GWAS 39 (Online Methods). Application of cross-trait LDSC 7 to estimate the genetic correlation provided further evidence of shared genetic structure between MDD and schizophrenia (r g = 0.47, standard error (s.e.) = 0.07, P = 1.61 × 10 −10 ), of similar magnitude to previous reports 7 . However, the BUHMBOX P value was not significant (P = 0.28), indicating no excess positive correlations among schizophrenia-associated loci in MDD cases (Fig. 6 and Supplementary Table 4) . Our findings suggest no evidence of a subgroup of schizophrenia-like MDD cases. However, we note that we lacked adequate statistical power to detect heterogeneity in the context of a small heterogeneity proportion. Given the MDD sample size and the number of currently known schizophrenia risk loci, there was 53% power at π = 0.20 but only 25% power at π = 0.10 (Fig. 5) .
(Supplementary
DISCUSSION
BUHMBOX can be used to determine whether shared genetic structure between traits is the consequence of heterogeneity or pleiotropy on the basis of SNP genotype data alone. It can help to interpret recent observations of shared genetic structures in complex traits, including autoimmune, neuropsychiatric, and metabolic diseases. The intuition behind BUHMBOX is that, if heterogeneity exists, independent loci will show nonrandom positive correlations. Hence, correcting for population structure and long-range LD is critical for this approach to be effective. We emphasize that it is necessary to appropriately interpret the source of heterogeneity, which will depend on the biological and clinical relationship between the two traits. We provide detailed information to guide interpretation in the Supplementary Note.
We demonstrated that genetic sharing among autoimmune diseases is due to pleiotropy, noting that for a few traits we had only modest power (Fig. 5) . One notable exception was seronegative RA, which might contain misclassified seropositive RA cases. The results presented here demonstrate that seronegative RA is a heterogeneous phenotype with respect to genetic overlap with seropositive RA, bringing clarity to an ongoing debate about the nature of this disease. In contrast, we were underpowered to draw more definitive conclusions as to whether a subset of MDD cases are genetically similar to schizophrenia cases; as MDD cohorts increase in size, we will be able to reassess more accurately whether smaller proportions of heterogeneity might partially explain observed coheritability. Our results are consistent with recent analyses concluding that pleiotropy among psychiatric diseases is unlikely to be explained by misclassifications alone 17 .
We showed that the power of BUHMBOX is a function of sample size, π, and the number, effect sizes, and allele frequencies of risk loci. Power to detect subtle heterogeneity (π <0.1) in current data sets is limited. However, in future studies, increasing sample size and the number of known associated loci will augment power. One potential strategy to augment power is to use a polygenic modeling 3,12,13 approach, including a larger number of SNPs with less stringent significance thresholds ( Supplementary Fig. 4 and Supplementary Note).
BUHMBOX has certain key caveats. First, it is designed to detect a specific type of heterogeneity resulting from the presence of a subgroup comprising a known second trait. Thus, BUHMBOX cannot currently be applied agnostically to detect the presence of heterogeneity in a data set. Second, BUHMBOX requires prior knowledge of associated loci and their effect sizes. For diseases with few known associated loci, BUHMBOX may perform suboptimally. Also, if known effect size estimates are inaccurate, power may decrease because appropriate weighting is crucial (Fig. 2) . Third, BUHMBOX requires individual-level genotype data for a limited number of loci. Fourth, BUHMBOX can be sensitive to confounding factors. We recommend careful control of LD npg t e c h n i c a l r e p o r t s and population structure using LD pruning and principal components. When comparing BUHMBOX to existing approaches, we focused on the GRS method. However, the results of our comparison also apply to other existing methods such as mixed-model-based approaches 5, 6 and LD-score-based approaches 7 , which are similar to the GRS approach in the sense that they detect both pleiotropy and heterogeneity. We expect that BUHMBOX will complement any of these methods to facilitate interpretation of observed genetic sharing between traits. Our statistical approach may be extended to have application beyond heterogeneity, including identification of missing heritability resulting from this type of heterogeneity 41 . These applications will become more feasible as functional annotations of SNPs advance in the coming years.
URLs. BUHMBOX software, https://www.broadinstitute.org/mpg/ buhmbox/; ImmunoBase, http://www.immunobase.org/.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Genetic risk score approach. Given M independent risk loci associated with D B , we calculated the GRS of individual i as
where x ij is the risk allele dosage for individual i at marker j and β j is the effect size (log-transformed OR) of the risk allele at marker j for disease D B . The GRS approach calculates GRSs for all individuals and associates GRSs with case/control status of D A . In the logistic regression framework for associating GRSs and D A status, we can obtain the regression coefficient for the GRS (β GRS ). We previously showed that β GRS approximates the proportion of D A cases that are genetically D B cases (heterogeneity proportion, π) if we assume that there is no pleiotropy and the GRS association is solely driven by a subgroup 38 . Thus, β GRS represents an upper bound of π. Within each subgroup, we generated genotypes assuming that risk alleles were distributed according to Hardy-Weinberg equilibrium and that risk loci were independent. We assumed Hardy-Weinberg equilibrium in cases because we assumed an additive disease model. Then, we applied BUHMBOX to calculate the P value. We repeated this 1,000 times to approximate power as the proportion of simulations with P ≤ 0.05. We evaluated power for different values of N, M, and π. Under the assumption that the risk loci were independent, the FPR simulation was equivalent to the power simulation described above, with the only difference being that π was set to 0, which forced the null hypothesis. We measured the FPR by assuming N = 1,000 and M = 20 and constructing 1,000,000 such studies.
Linkage disequilibrium simulations. To simulate realistic LD, we used chromosome 22 data from control individuals in the Swedish EIRA cohort of the RA data set (2,762 cases and 1,940 controls) 30 . We assigned half of control individuals as cases and the rest as controls. To generate 1,000 random sets of SNPs, we began from all SNPs and thinned the SNP set by tenfold with different seed numbers using PLINK 45 (with the command option --thin 0.1). We then pruned each of the 1,000 data sets using PLINK 45 with an r 2 criterion of 0.5 or 0.1.
Population stratification simulations.
To assess the effects of population stratification, we conducted two sets of simulations. For the first, we used data from HapMap 31 release 23 (60 CEU founders, 60 YRI founders, and 90 JPT + CHB founders), setting CEU + YRI individuals as cases and JPT + CHB individuals as controls. We calculated principal components after LD pruning (r 2 <0.1). For D B -associated SNPs, we randomly selected 5,000 sets of 22 independent SNPs; we selected a single SNP from each autosome. For the second simulation, we used genotype data from a northern European RA cohort (Swedish EIRA; 2,762 cases and 1,940 controls) and a southern Europe cohort (Spain; 807 cases and 399 controls) from the RA data set 30 . For this simulation, we used SNPs that we had generated for LD simulations (described above; thinned from Swedish EIRA chromosome 22 with criterion r 2 <0.1), by setting the Swedish samples as cases and adding the Spanish samples as controls.
